IsoRay (ISR) Earns Buy Rating from Analysts at Ascendiant Capital Markets

Equities researchers at Ascendiant Capital Markets assumed coverage on shares of IsoRay (NYSEAMERICAN:ISR) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating and a $1.00 price target on the healthcare company’s stock. Ascendiant Capital Markets’ target price points to a potential upside of 138.10% from the company’s current price.

Separately, Maxim Group set a $2.00 target price on IsoRay and gave the stock a “buy” rating in a report on Thursday, February 8th.

NYSEAMERICAN:ISR traded down $0.01 during mid-day trading on Monday, reaching $0.42. 76,400 shares of the company’s stock traded hands, compared to its average volume of 132,769. IsoRay has a 12-month low of $0.38 and a 12-month high of $0.64.

IsoRay (NYSEAMERICAN:ISR) last announced its quarterly earnings results on Thursday, February 8th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%. The business had revenue of $1.54 million for the quarter.

WARNING: This piece of content was originally published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2018/04/02/isoray-isr-earns-buy-rating-from-analysts-at-ascendiant-capital-markets.html.

IsoRay Company Profile

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply